REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

MEVOPUR COLORANTS • Standard colors in PP and PE to shorten time-to-market • Custom colors matched to Pantone, RAL or other color reference • White colorants for pharmaceutical packaging for LDPE, HDPE and PP with opacity to reach USP chapter MEVOPUR FUNCTIONAL ADDITIVES • Antistatic formulation with good flow/impact for injection molding • Amide- and amine-free antistatic for film in contact with API (Active Pharmaceutical Ingredients) • UV blocking for transparent PP and PE packaging to meet USP chapter • Non-migrating friction reduction/processing aid for PE and PP • Laser marking/welding additive for fast, reliable marking/assembly • MVTR (Moisture Vapor Transmission Rate) reduction for HDPE to improve shelf-life • Thermal protection of the polymer during processing • Gamma/e-beam sterilization protection for PP (up to 50kGy) with color compensation for reduced yellowing REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Bormed™ is a registered trademark of Borealis Healthcare use limitations apply—see below.

Corporate seat Amsterdam First entry in Business Register 12-04-2006 Date of deed of incorporation 11-04-2006 Date of deed of last amendment to the Articles of Association 12-04-2021 Issued capital EUR 19.593,63 Paid-up capital EUR 19.593,63 Filing of the annual accounts The annual accounts for the financial year 2019 were filed on 01-07-2020.

OFF-ROAD VEHICLE MANUFACTURER S E A T P A N • Consolidate parts to reduce assembly time and lower manufacturing costs • Maintain performance while replacing metal seat pan with lightweight composite material • Aided consolidation of multiple metal parts and fasteners into a single injection molded component, lowering costs $100k year • Saved time and money using FEA validation to confirm real-world performance before building tooling • Created full-size 3D printed prototypes to test fit and function Complēt™ Long Glass Fiber Nylon Composite KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION METAL REPLACEMENT + COST SAVINGS LEARN MORE Copyright © 2020, Avient Corporation.

Annual Report | 2024 2 STOCK EXCHANGE LISTING Avient's Common Stock is listed on the New York Stock Exchange, Symbol: AVNT SHAREHOLDER INQUIRIES If you have any questions concerning your account as a shareholder, name or address changes, inquiries regarding stock certificates, or if you need tax information regarding your account, please contact our transfer agent: Equiniti Trust Company, LLC 1110 Centre Pointe Curve, Suite 101 Mendota Heights, MN 55120-4100 Phone: 1-855-598-2615 or 1-651-450-4064 www.shareowneronline.com Additional information about Avient, including current and historic copies of Annual Reports on Form 10-K and other reports filed with the Securities and Exchange Commission, is available online at www.avient.com or free of charge from: Investor Relations Avient Corporation 33587 Walker Road Avon Lake, Ohio 44012 Phone: 1-440-930-1000 ANNUAL MEETING The annual meeting of Avient will be held virtually via live webcast at 9:00 a.m. FINANCIAL INFORMATION Security analysts and representatives of financial institutions are invited to contact: Joe Di Salvo Vice President, Treasurer and Investor Relations Phone: 1-440-930-1921 Email: giuseppe.disalvo@avient.com AUDITORS Ernst & Young LLP North Point Tower II, Suite 1800 1001 Lakeside Ave Cleveland, OH 44114 INTERNET ACCESS Information on Avient’s products and services, news releases, corporate governance, EDGAR filings, Reports on Forms 10-K and 10-Q, etc. as well as an electronic version of this annual report, are available on the Internet at www.avient.com. THIS PAGE IS NOT PART OF AVIENT’S FORM 10-K FILING THIS PAGE IS NOT PART OF POLYONE’S FORM 10-K FILINGTHIS PAGE IS NOT PART OF POLYONE’S FORM 10-K FILINGTHIS PAGE IS NOT PART OF AVIENT’S FORM 10-K FILING Reconciliation of Non-GAAP Financial Measures (Unaudited) (In millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

2) Based on information contained in a Schedule 13G/A filed by The Vanguard Group with the SEC on February 13, 2024. Patterson 14,850 76,944 26,958 Company Contributions to Qualified Savings Plan. This process, which is commonly referred to as “householding,” potentially provides extra convenience for shareholders and cost savings for companies.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Available as additive concentrates, ready-to-use additive formulations or ready-to-use additive/ colorant formulations for different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request; exceptions may occur Healthcare use limitations apply—see below.

AVIENT SOLUTION ADDRESSES CRITICAL MANUFACTURING PRODUCTIVITY ISSUES AND DELIVERS OVER $100,000 PER YEAR IN SAVINGS With the Avient material, the manufacturer is expected to save $122,000 per year vs. silicone. Even after the cost of the new tooling, the company will save about $72,000 the first year, an impressive and rapid return on the investment in new tooling.

As a result of the system-based cost savings and improved supply reliability, the manufacturer made the decision to proceed with the Avient solution. Cost savings: The hose manufacturer is saving $33,000 per year by using Versalloy TPV instead of its previous material. These savings resulted from lower specific gravity of the Avient material (0.88 compared to 0.95) and a 50% reduction in scrap rate.

WOOD PLASTIC COMPOSITE (WPC) MFG S H E E T A N D D E C K I N G • Lightweighting solution offering energy savings and manufacturing efficiencies • Reduced downtime associated with poor quality rejections • Consistent and uniform cell structure in decking material • Compatibility with mono-core extrusion formula (rice hull bio-filler and virgin PVC) when used with a chemical foaming additive • Density control of 0.60-0.65 g/cc in production • Provided a CFA solution that offered energy savings, process optimization, and extended manufacturing run times • Enabled improved performance results and enhanced process control • Allowed tighter tolerance control with uniform cell structure, eliminating voids and surpassing density target ($100K savings) • Increased productivity and aesthetic finish with secondary operations (sanding) KEY REQUIREMENTS Excelite™ Chemical Foaming Additives (CFA) WHY AVIENT?